Intensity-modulated radiotherapy reduces acute and delayed G2+GI toxicities versus 3D-CRT in high-risk prostate cancer
Post hoc analysis shows IMRT reduces radiation side effects for high-risk prostate cancer
This post hoc analysis of a Phase III randomized controlled trial evaluated intensity-modulated radiotherapy (IMRT) versus three-dimensional…
A post hoc analysis of a Phase III trial found that intensity-modulated radiotherapy reduced radiation side effects compared to older techni…
Time to biochemical progression predicts second events in high-risk prostate cancer
Longer time to progression predicts better outcomes in prostate cancer
This phase 3 RCT of 413 men with high-risk localized prostate cancer found that a longer time from randomization to biochemical progression …
Men with high-risk prostate cancer who had a longer time before their cancer worsened were less likely to have further progression or spread…
Liquid biopsy shows high sequencing success in high-risk localized prostate cancer feasibility study
Blood Tests Replace Biopsies for Prostate Cancer
A phase 2 neoadjuvant trial in 22 patients with high-risk localized prostate cancer found liquid-based genomic profiling achieved 100% seque…
A simple blood draw now replaces painful prostate biopsies, capturing the same genetic details doctors need to pick the best treatment.
Research across Cancer
Related studies from across the Cancer family.
Enzalutamide added to ADT improves survival in APIC-negative metastatic hormone-sensitive prostate cancer
Trial shows enzalutamide helps specific patients with prostate cancer
This randomized controlled trial analyzed 492 patients with metastatic hormone-sensitive prostate cancer to evaluate the impact of the APIC …
A new analysis shows that a specific biomarker can help doctors identify which prostate cancer patients may benefit most from enzalutamide t…
Systemic barriers like delayed diagnosis and limited surgery impact survival in high-grade gliomas
Systemic Barriers Impact Survival for Patients with High-Grade Gliomas
This meta-analysis of 30 independent studies evaluates survival outcomes for high-grade gliomas in low- and middle-income countries. Finding…
Limited access to surgery, chemotherapy, and early diagnosis creates significant hurdles for patients with high-grade gliomas in developing …
Rezvilutamide plus ADT with efavirenz-based ART yields PSA decline in one HIV-positive mHSPC patient
Rezvilutamide Shows Promise for Prostate Cancer in HIV Patients
This is a single-patient case report describing rezvilutamide plus androgen deprivation therapy in an HIV-positive patient with high-volume …
A single patient with both HIV and advanced prostate cancer showed significant improvement after starting a specific combination of treatmen…
Docetaxel and PARPi additions to ARPI and ADT improve progression-free survival in mHSPC
New data shows potential benefits for advanced prostate cancer patients
This network meta-analysis of 18,689 patients with metastatic hormone-sensitive prostate cancer (mHSPC) evaluated first-line systemic combin…
New data suggests that adding specific drugs to standard hormone therapy may help slow the growth of advanced prostate cancer.
Integrated Prognostic Criteria Improve Survival Stratification in Metastatic Castration-Sensitive Prostate Cancer
Trial shows improved prediction of survival in prostate cancer
Combining CHAARTED and LATITUDE criteria enhances prognostic accuracy for mCSPC, though specific treatment benefits in certain subgroups rem…
A new way to combine two scoring systems helps doctors better predict how patients with advanced prostate cancer will respond to treatment.
Lead-in ADT reduces grade ≥3 neutropenia incidence in metastatic hormone-sensitive prostate cancer patients
Lead-in therapy may reduce severe low white blood cell counts
This post hoc analysis of a phase 3 trial and real-world validation study evaluated lead-in androgen-deprivation therapy (ADT) for patients …
A new look at clinical data suggests that a lead-in hormone treatment can help prevent serious low white blood cell counts in prostate cance…
Metachronous pancreatic metastasis from ovarian cancer is rare, mostly high-grade serous
Ovarian cancer can spread to pancreas, rare review finds
This systematic review of 7 studies (8 cases) found that metachronous pancreatic metastasis from ovarian cancer is rare and most often origi…
A rare spread of ovarian cancer to the pancreas may be treatable with surgery or chemo, but evidence is thin.
Reactive oxygen species promote tumorigenic programs and platinum-based chemotherapy resistance in high-grade serous ovarian cancer
Reactive Oxygen Species May Drive Ovarian Cancer Progression
This narrative review of 19 in vitro studies synthesizes how reactive oxygen species (ROS) drive tumor progression, metastatic potential, an…
New research explores how reactive oxygen species (ROS) may help ovarian cancer cells grow, spread, and resist common chemotherapy treatment…
CAR T-cell therapies targeting specific antigens show potential for treating pediatric CNS tumors
New CAR T-cell therapies show promise for pediatric brain tumors
This narrative review synthesizes 18 studies, including preclinical and early-phase clinical trials, regarding CAR T-cell therapy for pediat…
CAR T-cell therapy is showing potential to shrink tumors and extend life in children with aggressive brain cancers like DIPG.
Targeted cytokine delivery platforms in canine oncology provide data for human immuno-oncology dose selection
Cytokine Therapies Show Potential for Treating Canine Cancers
This mini review synthesizes evidence on targeted cytokine delivery platforms, such as IL-12 and IFN-beta, in dogs with various spontaneous …
New research explores how targeted cytokine delivery systems can treat various cancers in dogs and provide data for future human cancer trea…
Immunohistochemical profiling helps differentiate synchronous primary breast invasive carcinoma from metastatic ovarian carcinoma
One woman diagnosed with two different types of cancer simultaneously
This case report and literature review describes a patient with concurrent primary breast cancer and metastatic high-grade serous ovarian ca…
A rare case reveals how one patient can have both breast and ovarian cancer at once, highlighting a complex diagnostic challenge.
Intracranial immunotherapy delivery does not improve survival for pediatric high-grade glioma compared to systemic administration
Intracranial Delivery Shows Higher Neurotoxicity Risk in Pediatric Brain Tumors
This meta-analysis of 22 studies evaluated intracranial versus systemic immunotherapy delivery in pediatric patients with high-grade and dif…
New analysis shows that while delivery methods do not change survival for pediatric brain tumors, some routes carry a higher risk of severe …